UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 15, 2008 (February 11, 2008)
ALNYLAM PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
| Delaware
|
|
000-50743
|
|
77-0602661 |
|
|
|
|
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 300 Third Street, Cambridge, Massachusetts
|
|
02142 |
|
|
|
|
| (Address of Principal Executive Offices)
|
|
(Postal Code) |
Registrant’s telephone number, including area code: (617) 551-8200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
|
|
| ¨ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
| ¨ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
| ¨ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
|
| ¨ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers; Compensatory Arrangements of Certain Officers.
On February 11, 2008, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the
“Company”) elected Edward M. Scolnick, M.D. as a Class III director with a term expiring at the
annual meeting of stockholders to be held in 2010. In connection with
his election to the Board, Dr. Scolnick received a stock option
grant for 45,000 shares of common stock of the Company, vesting
annually over three years, and will be compensated as a director
pursuant to the Company’s compensation policy for non-employee directors, which is described in our
Proxy Statement for the 2007 Annual Meeting of Stockholders filed with the Securities and Exchange
Commission on April 30, 2007.